Startups

RLTYco: $20 Million (Series A) Raised For Giving Agents Same-Day Commission Advances And Other Benefits

By Amit Chowdhry ● Jan 12, 2025

RLTYco, a New York-based full-service provider of comprehensive resources for real estate professionals, announced the closing of a $20 million Series A funding round led by Altriarch. The funding round also included participation from existing investors, including Andrew Dodge, entrepreneur and angel investor, Christopher Schmidt, Executive Vice President at Related Companies, and SERHANT. Ventures (SERHANT.’s education division that develops, creates, and produces resources and solutions for agents in today’s new marketplace). Ryan Serhant, CEO and founder of SERHANT., is a partner, advisor and ambassador via SERHANT. Ventures.

Grand Games: $30 Million (Series A) Raised To Accelerate Growth

By Amit Chowdhry ● Jan 12, 2025

Grand Games, a gaming studio behind the widely loved Magic Sort mobile game, announced it has raised a $30 million Series A round, marking its arrival as the latest up-and-coming studio to emerge from Istanbul, the gaming powerhouse that brought forth Dream Games and Peak Games. Balderton Capital led the round with participation from existing investors Bek Ventures (formerly known as Earlybird Digital East), Laton Ventures, and angel investor Mert Gür.

Oddball Raises Growth Investment From Falfurrias Management

By Amit Chowdhry ● Jan 12, 2025

Private equity firm Falfurrias Management Partners announced its growth investment in Oddball. This leading digital services agency transforms and modernizes how government organizations interact with their constituents.

Prudentia Sciences: AI-Based Life Sciences Marketplace Company Raises $7 Million

By Amit Chowdhry ● Jan 12, 2025

Prudentia Sciences, an AI-based technology platform for life sciences announced its public launch, supported by $7 million in funding. This funding round was led by GV, with participation from Iaso Ventures and Virtue.

Tenvie Therapeutics Raises $200 Million For Delivering Small Molecule Therapies

By Amit Chowdhry ● Jan 12, 2025

Advanced Ionics: Green Hydrogen Electrolyzer Company Raises $6.7 Million

By Amit Chowdhry ● Jan 12, 2025

Advanced Ionics, a developer of a new class of green hydrogen electrolyzers aimed at accelerating decarbonization, announced that it raised an additional $6.7 million in funding from strategic investors JERA, Lummus Venture Capital, the Argosy Foundation, and existing investors Clean Energy Venture Group and bp Ventures.

Absci Raising $20 Million From AMD

By Amit Chowdhry ● Jan 12, 2025

Absci Corporation, a data-first generative AI-based drug creation company, announced a strategic collaboration with AMD to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. And AMD will also make a $20 million investment in Absci, structured as a private investment in public equity (PIPE), highlighting the growing demand for innovative AI applications in drug discovery.

Vensana Capital: $425 Million Fund III Closed For Investing In Breakthrough Medical Technologies

By Amit Chowdhry ● Jan 12, 2025

Vensana Capital announced the closing of Vensana Capital III with $425 million in committed capital. This fund was oversubscribed at its hard cap with the support of the firm’s existing limited partners alongside select new institutional investors, and it brings Vensana’s total capital under management to about $1 billion.

Leyden Labs: $70 Million Secured For Advancing Intranasal Antibody Programs

By Amit Chowdhry ● Jan 12, 2025

Leyden Laboratories announced it has raised $70 million in funding to advance its Mucosal Protection Platform. This funding round was supported by co-leads ClavystBio and Polaris Partners, with participation by Qiming Venture Partners and existing investors. And the company’s syndicate of VC investors now includes GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio, Polaris Partners, Qiming Venture Partners, Invus, Byers Capital / Brook Byers, Bluebird Ventures, and Softbank Vision Fund 2.

RyboDyn: $4 Million (Pre-Seed) Raised To Pioneer Development Of First-In-Class Immunotherapies

By Amit Chowdhry ● Jan 12, 2025

RyboDyn announced the discovery of a new proteome and the successful closing of a $4 million pre-seed financing round to advance its mission of targeting the dark proteome to develop novel immunotherapies. The funding round was co-led by Genedant Capital and SeaX Ventures, with significant participation from SOSV and Swell VC as part of the investment syndicate.

RheumaGen: Gene Therapy Company Raises $15 Million (Series A)

By Amit Chowdhry ● Jan 11, 2025

RheumaGen - a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases - announced the closing of a $15 million Series A financing co-led by SPRIM Global Investments and William Taylor Nominees.